Loading...

Jacobio Pharmaceuticals Group Co., Ltd.

1167.HK•HKSE
Healthcare
Biotechnology
HK$4.58
HK$0.35(8.27%)

Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) Stock Overview

Explore Jacobio Pharmaceuticals Group Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap3.4B
P/E Ratio-19.65
EPS (TTM)$-0.22
ROE-0.17%
Fundamental Analysis

AI Price Forecasts

1 Week$5.93
1 Month$5.08
3 Months$1.72
1 Year Target$0.75

1167.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 66.02, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.75.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -19.65 and a market capitalization of 3.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

66.02RSI (14)
0.45MACD
42.70ADX
Stats data is not available for 1167.HKStats details for 1167.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1167.HKAnalyst Recommendations details for 1167.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.

CEO

Yinxiang Wang

Employees

257

Headquarters

Building F2, Beijing

Founded

2020

Frequently Asked Questions

;